Safety Reading Notes

Read safety context beside the research guide.

The 5-HT1A source set should still be read with safety context in mind. Mechanistic or preclinical evidence should not be converted into consumer instructions, and product identity can change how closely a source applies. PMID 41545891

PubMed For Dummies Article

5-HT1A Evidence Review: the long-form source walk-through

Quick read
  • 5-HT1A currently has 35 source-backed evidence row(s), so this page should be read as a research guide rather than a single conclusion. PMID 41545891
  • The evidence classes most visible in the row language are mechanistic or pharmacological (17), insufficient (16), and preclinical (2). PMID 30405366
  • The study-design language most visible in the row language is Animal study (15), Narrative or expert review (13), Cellular or in vitro study (3), and other mapped categories (3). PMID 29057454
  • The repeated topics are receptor, target, or pharmacology mechanisms (15), nausea-related or inflammation-related outcomes (7), receptor, target, metabolic, or pharmacology mechanisms (3), Appetite and metabolic outcomes (2), and other mapped categories (8), which tells the reader where to start opening PubMed and DOI links. PMID 32488349

Start with the research question

5-HT1A is built from 35 source-backed evidence row(s) and 30 research source(s). The current evidence classes read as mechanistic or pharmacological (17), insufficient (16), and preclinical (2), and the study-design language most often reads as Animal study (15), Narrative or expert review (13), Cellular or in vitro study (3), and other mapped categories (3). PMID 41545891

The row-level question is not simply whether 5-HT1A is "good" or "bad." The useful question is what each row studied, what evidence class it received, and whether the source is close to the reader's actual question. The most repeated row topics are receptor, target, or pharmacology mechanisms (15), nausea-related or inflammation-related outcomes (7), receptor, target, metabolic, or pharmacology mechanisms (3), Appetite and metabolic outcomes (2), and other mapped categories (8). PMID 33522084

Human evidence 0 rows

Rows involving human participants, patients, or clinical source language. These rows are closer to everyday reader questions, but still depend on population, dose, route, comparator, and endpoint. PMID 31897571

Preclinical evidence 2 rows

Animal, cellular, or model-based rows. These can explain why a topic is being studied, but they should not be read as human-health instructions. PMID 23121618

Mechanistic evidence 17 rows

Rows about receptors, enzymes, channels, metabolism, binding, signaling, or pharmacology. These explain plausibility without proving a consumer outcome. PMID 26439367

Limits and uncertainty 17 rows

Rows where safety, tolerability, risk, product limits, or insufficient evidence need to stay visible next to the rest of the article. PMID 24595502

The lane labels are not a quality score. They are a reading method: keep human evidence, preclinical evidence, mechanisms, and uncertainty in separate mental boxes before deciding what a source can actually support. PMID 33522084

Where this page has the most source density

The largest bucket surfaced for this page is nausea-related or inflammation-related outcomes. That does not automatically mean the topic is settled; it means this is where the current source trail is densest. The next visible bucket is receptor, target, or pharmacology mechanisms, which gives readers another way to see what the literature repeatedly circles. PMID 41545891

Source density should be read with evidence posture. A bucket can contain many rows and still be limited if the studies are indirect, mixed, preclinical, product-specific, or mostly review-level. The paragraphs below name the buckets directly and keep each explanation connected to a source record. PMID 33522084

Bucket chapters: what the literature is circling

nausea-related or inflammation-related outcomes

7 research sources 7 rows (125-133) Mechanistic and preclinical research summary: insufficient (1), mechanistic or pharmacological (5), preclinical (1)

5-HT1A appears in rows studying nausea-related or inflammation-related outcomes. It currently draws from 7 research source(s), so the population, dose, route, and endpoint should be checked before reading across contexts. PMID 41545891

Read this bucket as closer to a real-world question, then check the study population, dose, product, comparator, and endpoint before generalizing beyond the source. PMID 41545891

  • Evidence row 125

    CBDA studied for nausea-related or inflammation-related outcomes; evidence class: insufficient (population or model: Pediatric, adolescent, or developmental context mentioned; study design: Narrative or expert review; outcome m... PMID 41545891

  • Evidence row 133

    CBDA studied for nausea-related or inflammation-related outcomes; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Human clinical study; outcome measure: nausea-related... PMID 24595502

receptor, target, or pharmacology mechanisms

6 research sources 6 rows (253-261) Mechanistic and preclinical research summary: insufficient (3), mechanistic or pharmacological (2), preclinical (1)

5-HT1A appears in rows about receptor, target, or pharmacology mechanisms mechanisms. It currently draws from 6 research source(s), and mechanistic evidence should stay separate from human-outcome evidence. PMID 33522084

Read this bucket as closer to a real-world question, then check the study population, dose, product, comparator, and endpoint before generalizing beyond the source. PMID 33522084

  • Evidence row 253

    CBD modulates receptor, target, or pharmacology mechanisms; evidence class: insufficient (population or model: Animal model mentioned; study design: Animal study; outcome measure: receptor, target, or pharmacology mechanisms). PMID 33522084

  • Evidence row 261

    CBD modulates receptor, target, or pharmacology mechanisms; evidence class: preclinical (population or model: Animal model mentioned; study design: Animal study; outcome measure: receptor, target, or pharmacology mechanisms). PMID 22585736

receptor, target, or pharmacology mechanisms

5 research sources 5 rows (259-267) Mechanistic research summary: insufficient (3), mechanistic or pharmacological (2)

5-HT1A appears in rows about receptor, target, or pharmacology mechanisms mechanisms. It currently draws from 5 research source(s), and mechanistic evidence should stay separate from human-outcome evidence. PMID 21557733

Read this bucket as mechanism or pharmacology context. Mechanisms can make the biology easier to understand, but they are not the same thing as a demonstrated effect in people. PMID 21557733

  • Evidence row 259

    Cannabinoids modulates receptor, target, or pharmacology mechanisms; evidence class: insufficient (study design: Narrative or expert review; outcome measure: receptor, target, or pharmacology mechanisms). PMID 21557733

  • Evidence row 267

    Cannabinoids modulates receptor, target, or pharmacology mechanisms; evidence class: mechanistic or pharmacological (population or model: Cellular or in vitro model mentioned; study design: Cellular or in vitro study; outcome m... PMID 11347816

receptor, target, or pharmacology mechanisms

4 research sources 4 rows (258-265) Mechanistic research summary: insufficient (2), mechanistic or pharmacological (2)

5-HT1A appears in rows about receptor, target, or pharmacology mechanisms mechanisms. It currently draws from 4 research source(s), and mechanistic evidence should stay separate from human-outcome evidence. PMID 36439263

Read this bucket as mechanism or pharmacology context. Mechanisms can make the biology easier to understand, but they are not the same thing as a demonstrated effect in people. PMID 36439263

  • Evidence row 258

    Endocannabinoids modulates receptor, target, or pharmacology mechanisms; evidence class: insufficient (study design: Systematic review; outcome measure: receptor, target, or pharmacology mechanisms). PMID 36439263

  • Evidence row 265

    Endocannabinoids modulates receptor, target, or pharmacology mechanisms; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: re... PMID 28861502

Receptor, target, metabolic, and pharmacology mechanisms

3 research sources 3 rows (567-578) Mechanistic research summary: insufficient (1), mechanistic or pharmacological (2)

5-HT1A appears in rows about Receptor, target, metabolic, and pharmacology mechanisms mechanisms. It currently draws from 3 research source(s), and mechanistic evidence should stay separate from human-outcome evidence. PMID 33168643

Read this bucket as mechanism or pharmacology context. Mechanisms can make the biology easier to understand, but they are not the same thing as a demonstrated effect in people. PMID 33168643

  • Evidence row 567

    CBG modulates receptor, target, metabolic, or pharmacology mechanisms; evidence class: insufficient (study design: Narrative or expert review; outcome measure: receptor, target, metabolic, or pharmacology mechanisms). PMID 33168643

  • Evidence row 578

    CBG modulates receptor, target, metabolic, or pharmacology mechanisms; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: receptor, target,... PMID 37305529

Appetite and metabolic outcomes

2 research sources 2 rows (623-627) Mechanistic research summary: insufficient (1), mechanistic or pharmacological (1)

5-HT1A appears in rows studying Appetite and metabolic outcomes. It currently draws from 2 research source(s), so the population, dose, route, and endpoint should be checked before reading across contexts. PMID 37305529

Read this bucket as mechanism or pharmacology context. Mechanisms can make the biology easier to understand, but they are not the same thing as a demonstrated effect in people. PMID 37305529

  • Evidence row 623

    CBG studied for Appetite and metabolic outcomes; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: appetite-related, weight, glucose, or me... PMID 37305529

  • Evidence row 627

    CBG studied for Appetite and metabolic outcomes; evidence class: insufficient (study design: Narrative or expert review; outcome measure: appetite-related, weight, glucose, or metabolic outcomes). PMID 36397993

CB1

1 research source 859 Mechanistic research summary: mechanistic or pharmacological (1)

5-HT1A appears in rows about CB1 mechanisms. It currently draws from 1 research source(s), and mechanistic evidence should stay separate from human-outcome evidence. PMID 35595026

Read this bucket as mechanism or pharmacology context. Mechanisms can make the biology easier to understand, but they are not the same thing as a demonstrated effect in people. PMID 35595026

  • Evidence row 859

    Cannabinoids modulates CB1; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Human clinical study; outcome measure: CB1 neurobehavioral, appetite, meta... PMID 35595026

Inflammation-related outcomes

1 research source 71 Mapped evidence with interpretation limits: insufficient (1)

5-HT1A appears in rows studying Inflammation-related outcomes. It currently draws from 1 research source(s), so the population, dose, route, and endpoint should be checked before reading across contexts. PMID 41545891

Read this bucket as an uncertainty marker. The source trail exists, but the current evidence posture is not strong enough for a broad plain-English conclusion. PMID 41545891

  • Evidence row 71

    CBC studied for Inflammation-related outcomes; evidence class: insufficient (population or model: Pediatric, adolescent, or developmental context mentioned; study design: Narrative or expert review; outcome measure: inflammatio... PMID 41545891

Human evidence, mechanisms, and safety are different lanes

This page currently separates human evidence (0 row(s)), mechanistic evidence (17 row(s)), and safety/tolerability context (1 row(s)). That separation is the heart of the site. Mechanistic evidence can make a topic biologically interesting, but it should not silently become a human outcome. PMID 41545891

Human evidence still depends on population, dose, route, duration, product identity, and endpoint. Safety rows belong in the same reading path as benefit-oriented rows because formulation, co-exposures, prescription medications, impairment context, and higher-risk populations can change how close a source is to a reader's question. PMID 33522084

What this does and does not mean

  • It means the page has a traceable source trail. It does not mean every bucket has the same clinical strength. PMID 23924692
  • It means mechanisms, animal models, human studies, safety rows, and insufficient-evidence rows are being kept visible as separate evidence types. PMID 39657242
  • It does not turn a preclinical mechanism into a consumer recommendation, and it does not treat one product, dose, route, or population as interchangeable with another. PMID 42212209

How to use the source table

The source-backed evidence table below is the audit trail. Each row keeps a public sentence connected to a source record when a PubMed ID or DOI is available. If a sentence feels important, the reader should be able to click through, inspect the study type, and decide whether the source is close to the question they care about. PMID 41545891

This is why the public page is intentionally layered. The top gives the reader a fast orientation. The bucket table groups repeated rows into readable topics. The article body explains the buckets using the actual evidence-row language. The source notes below walk through every evidence row before the source table repeats the technical trace. PMID 33522084

Source-reading checklist for 5-HT1A

  1. Open the linked PubMed or DOI record. PMID 40432283
  2. Check whether the source studied humans, animals, cells, chemistry, pharmacology, product testing, or a review of prior literature. PMID 36439263
  3. Compare the source product, dose, route, population, and endpoint to the question being asked. PMID 21557733
  4. Look for safety, tolerability, drug-interaction, impairment, pregnancy, pediatric, psychiatric, cardiovascular, and product-quality context before treating the bucket as settled. PMID 18755158
  5. Return to the evidence table when the article summary sounds too broad; the row is the audit unit. PMID 22585736

Source Notes

5-HT1A source-by-source reading notes

These notes pull every evidence row on this page into the readable article body before the source table repeats the audit trail. Each note keeps the row language beside the PubMed or DOI link when available.

  1. Evidence row 44

    THCA studied for THCA-specific safety, effect, or mechanism claims; evidence class: mechanistic or pharmacological (outcome measure: safety, effect, or mechanism claims). PMID 30405366

    Evidence class: mechanistic or pharmacological. Source: Cannabis Therapeutics and the Future of Neurology.
  2. Evidence row 70

    CBG studied for Pain-related outcomes; evidence class: insufficient (population or model: Pediatric, adolescent, or developmental context mentioned; study design: Narrative or expert review; outcome measure: pain-related outcomes). PMID 41545891

    Evidence class: insufficient; Study design: Narrative or expert review. Source: Therapeutic potential of acidic cannabinoids: an update.
  3. Evidence row 71

    CBC studied for Inflammation-related outcomes; evidence class: insufficient (population or model: Pediatric, adolescent, or developmental context mentioned; study design: Narrative or expert review; outcome measure: inflammation-related or pain-related outcomes). PMID 41545891

    Evidence class: insufficient; Study design: Narrative or expert review. Source: Therapeutic potential of acidic cannabinoids: an update.
  4. Evidence row 125

    CBDA studied for nausea-related or inflammation-related outcomes; evidence class: insufficient (population or model: Pediatric, adolescent, or developmental context mentioned; study design: Narrative or expert review; outcome measure: nausea-related or inflammation-related outcomes). PMID 41545891

    Evidence class: insufficient; Study design: Narrative or expert review. Source: Therapeutic potential of acidic cannabinoids: an update.
  5. Evidence row 127

    CBDA studied for nausea-related or inflammation-related outcomes; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Animal study; outcome measure: nausea-related or inflammation-related outcomes). PMID 29057454

    Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: Cannabidiolic acid methyl ester, a stable synthetic analogue of cannabidiolic acid, can produce 5-HT1A receptor-mediated suppression of nausea and anxiety in rats.
  6. Evidence row 129

    CBDA studied for nausea-related or inflammation-related outcomes; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: nausea-related or inflammation-related outcomes). PMID 32488349

    Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: Evaluation of repeated or acute treatment with cannabidiol (CBD), cannabidiolic acid (CBDA) or CBDA methyl ester (HU-580) on nausea and/or vomiting in rats and shrews.
  7. Evidence row 130

    CBDA studied for nausea-related or inflammation-related outcomes; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: nausea-related or inflammation-related outcomes). PMID 31897571

    Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: Effect of combined doses of Δ9-tetrahydrocannabinol and cannabidiol or tetrahydrocannabinolic acid and cannabidiolic acid on acute nausea in male Sprague-Dawley rats.
  8. Evidence row 131

    CBDA studied for nausea-related or inflammation-related outcomes; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: nausea-related or inflammation-related outcomes). PMID 23121618

    Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: Cannabidiolic acid prevents vomiting in Suncus murinus and nausea-induced behaviour in rats by enhancing 5-HT1A receptor activation.
  9. Evidence row 132

    CBDA studied for nausea-related or inflammation-related outcomes; evidence class: preclinical (population or model: Human participants or patients mentioned; study design: Animal study; outcome measure: nausea-related or inflammation-related outcomes). PMID 26439367

    Evidence class: preclinical; Study design: Animal study. Source: Neuromotor tolerability and behavioural characterisation of cannabidiolic acid, a phytocannabinoid with therapeutic potential for anticipatory nausea.
  10. Evidence row 133

    CBDA studied for nausea-related or inflammation-related outcomes; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Human clinical study; outcome measure: nausea-related or inflammation-related outcomes). PMID 24595502

    Evidence class: mechanistic or pharmacological; Study design: Human clinical study. Source: A comparison of cannabidiolic acid with other treatments for anticipatory nausea using a rat model of contextually elicited conditioned gaping.
  11. Evidence row 253

    CBD modulates receptor, target, or pharmacology mechanisms; evidence class: insufficient (population or model: Animal model mentioned; study design: Animal study; outcome measure: receptor, target, or pharmacology mechanisms). PMID 33522084

    Evidence class: insufficient; Study design: Animal study. Source: Differential contribution of CB1, CB2, 5-HT1A, and PPAR-γ receptors to cannabidiol effects on ischemia-induced emotional and cognitive impairments.
  12. Evidence row 254

    CBD modulates receptor, target, or pharmacology mechanisms; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: receptor, target, or pharmacology mechanisms). PMID 23924692

    Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: Motor effects of the non-psychotropic phytocannabinoid cannabidiol that are mediated by 5-HT1A receptors.
  13. Evidence row 255

    CBD modulates receptor, target, or pharmacology mechanisms; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: receptor, target, or pharmacology mechanisms). PMID 39657242

    Evidence class: insufficient; Study design: Narrative or expert review. Source: A novel insight into the antidepressant effect of cannabidiol: possible involvement of the 5-HT1A, CB1, GPR55, and PPARγ receptors.
  14. Evidence row 256

    CBD modulates receptor, target, or pharmacology mechanisms; evidence class: insufficient (population or model: Cellular or in vitro model mentioned; study design: Narrative or expert review; outcome measure: receptor, target, or pharmacology mechanisms). PMID 42212209

    Evidence class: insufficient; Study design: Narrative or expert review. Source: Cannabidiol: Pharmaceutical formulations and biomedical applications.
  15. Evidence row 257

    CBD modulates receptor, target, or pharmacology mechanisms; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Animal study; outcome measure: receptor, target, or pharmacology mechanisms). PMID 40432283

    Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: Cannabidiol dose dependently reduces alcohol intake in mice via a non-5-HT1A receptor mechanism: Exploration of other potential receptor targets.
  16. Evidence row 258

    Endocannabinoids modulates receptor, target, or pharmacology mechanisms; evidence class: insufficient (study design: Systematic review; outcome measure: receptor, target, or pharmacology mechanisms). PMID 36439263

    Evidence class: insufficient; Study design: Systematic review. Source: Cys-loop receptors on cannabinoids: All high?
  17. Evidence row 259

    Cannabinoids modulates receptor, target, or pharmacology mechanisms; evidence class: insufficient (study design: Narrative or expert review; outcome measure: receptor, target, or pharmacology mechanisms). PMID 21557733

    Evidence class: insufficient; Study design: Narrative or expert review. Source: Allosteric modulation of glycine receptors.
  18. Evidence row 260

    Endocannabinoids modulates receptor, target, or pharmacology mechanisms; evidence class: mechanistic or pharmacological (population or model: Cellular or in vitro model mentioned; study design: Cellular or in vitro study; outcome measure: receptor, target, or pharmacology mechanisms). PMID 18755158

    Evidence class: mechanistic or pharmacological; Study design: Cellular or in vitro study. Source: Subunit-specific modulation of glycine receptors by cannabinoids and N-arachidonyl-glycine.
  19. Evidence row 261

    CBD modulates receptor, target, or pharmacology mechanisms; evidence class: preclinical (population or model: Animal model mentioned; study design: Animal study; outcome measure: receptor, target, or pharmacology mechanisms). PMID 22585736

    Evidence class: preclinical; Study design: Animal study. Source: Cannabinoids suppress inflammatory and neuropathic pain by targeting α3 glycine receptors.
  20. Evidence row 262

    Endocannabinoids modulates receptor, target, or pharmacology mechanisms; evidence class: mechanistic or pharmacological (population or model: Cellular or in vitro model mentioned; study design: Cellular or in vitro study; outcome measure: receptor, target, or pharmacology mechanisms). PMID 16107637

    Evidence class: mechanistic or pharmacological; Study design: Cellular or in vitro study. Source: Glycine receptors in CNS neurons as a target for nonretrograde action of cannabinoids.
  21. Evidence row 263

    Cannabinoids modulates receptor, target, or pharmacology mechanisms; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: receptor, target, or pharmacology mechanisms). PMID 35091505

    Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: Mu Opioid Receptors Acutely Regulate Adenosine Signaling in Striatal Glutamate Afferents.
  22. Evidence row 264

    Cannabinoids modulates receptor, target, or pharmacology mechanisms; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: receptor, target, or pharmacology mechanisms). PMID 15589342

    Evidence class: insufficient; Study design: Narrative or expert review. Source: Sampling glutamate and GABA with microdialysis: suggestions on how to get the dialysis membrane closer to the synapse.
  23. Evidence row 265

    Endocannabinoids modulates receptor, target, or pharmacology mechanisms; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: receptor, target, or pharmacology mechanisms). PMID 28861502

    Evidence class: insufficient; Study design: Narrative or expert review. Source: Cannabinoids in Parkinson's Disease.
  24. Evidence row 266

    Cannabinoids modulates receptor, target, or pharmacology mechanisms; evidence class: insufficient (study design: Narrative or expert review; outcome measure: receptor, target, or pharmacology mechanisms). PMID 33631255

    Evidence class: insufficient; Study design: Narrative or expert review. Source: Tolerance to alcohol: A critical yet understudied factor in alcohol addiction.
  25. Evidence row 267

    Cannabinoids modulates receptor, target, or pharmacology mechanisms; evidence class: mechanistic or pharmacological (population or model: Cellular or in vitro model mentioned; study design: Cellular or in vitro study; outcome measure: receptor, target, or pharmacology mechanisms). PMID 11347816

    Evidence class: mechanistic or pharmacological; Study design: Cellular or in vitro study. Source: Activation of nicotinic receptors on GABAergic amacrine cells in the rabbit retina indirectly stimulates dopamine release.
  26. Evidence row 359

    THC modulates TRP channel activity or ionotropic cannabinoid target mechanisms; evidence class: insufficient (study design: Narrative or expert review; outcome measure: TRP channel activity or ionotropic cannabinoid target mechanisms). PMID 33168643

    Evidence class: insufficient; Study design: Narrative or expert review. Source: The Pharmacological Case for Cannabigerol.
  27. Evidence row 440

    THC studied for Psychiatric risk; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: psychiatric risk outcomes). PMID 33228239

    Evidence class: insufficient; Study design: Narrative or expert review. Source: Cannabidiol: A Potential New Alternative for the Treatment of Anxiety, Depression, and Psychotic Disorders.
  28. Evidence row 567

    CBG modulates receptor, target, metabolic, or pharmacology mechanisms; evidence class: insufficient (study design: Narrative or expert review; outcome measure: receptor, target, metabolic, or pharmacology mechanisms). PMID 33168643

    Evidence class: insufficient; Study design: Narrative or expert review. Source: The Pharmacological Case for Cannabigerol.
  29. Evidence row 570

    CBG modulates receptor, target, metabolic, or pharmacology mechanisms; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: receptor, target, metabolic, or pharmacology mechanisms). PMID 25269802

    Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: Colon carcinogenesis is inhibited by the TRPM8 antagonist cannabigerol, a Cannabis-derived non-psychotropic cannabinoid.
  30. Evidence row 578

    CBG modulates receptor, target, metabolic, or pharmacology mechanisms; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: receptor, target, metabolic, or pharmacology mechanisms). PMID 37305529

    Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: Cannabigerol modulates α2-adrenoceptor and 5-HT1A receptor-mediated electrophysiological effects on dorsal raphe nucleus and locus coeruleus neurons and anxiety behavior in rat.
  31. Evidence row 623

    CBG studied for Appetite and metabolic outcomes; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: appetite-related, weight, glucose, or metabolic outcomes). PMID 37305529

    Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: Cannabigerol modulates α2-adrenoceptor and 5-HT1A receptor-mediated electrophysiological effects on dorsal raphe nucleus and locus coeruleus neurons and anxiety behavior in rat.
  32. Evidence row 627

    CBG studied for Appetite and metabolic outcomes; evidence class: insufficient (study design: Narrative or expert review; outcome measure: appetite-related, weight, glucose, or metabolic outcomes). PMID 36397993

    Evidence class: insufficient; Study design: Narrative or expert review. Source: Pharmacological Aspects and Biological Effects of Cannabigerol and Its Synthetic Derivatives.
  33. Evidence row 754

    THCV studied for safety, tolerability, adverse-event, impairment, THC-interaction, or formulation-specific concerns; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Animal study; outcome measure: safety, tolerability, adverse-event, impairment, THC-interaction, or formulation-specific concerns). PMID 35303507

    Evidence class: insufficient; Study design: Animal study. Source: Role of Cannabidiol and Tetrahydrocannabivarin on Paclitaxel-induced neuropathic pain in rodents.
  34. Evidence row 859

    Cannabinoids modulates CB1; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Human clinical study; outcome measure: CB1 neurobehavioral, appetite, metabolic, pain, cognition, or synaptic mechanisms). PMID 35595026

    Evidence class: mechanistic or pharmacological; Study design: Human clinical study. Source: Cross state-dependent memory retrieval between cannabinoid CB1 and serotonergic 5-HT1A receptor agonists in the mouse dorsal hippocampus.
  35. Evidence row 1051

    CBG modulates TRPM8; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: TRPM8 channel activity, binding, signaling, or pharmacology). PMID 25269802

    Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: Colon carcinogenesis is inhibited by the TRPM8 antagonist cannabigerol, a Cannabis-derived non-psychotropic cannabinoid.